1. Home
  2. TLSA vs ORMP Comparison

TLSA vs ORMP Comparison

Compare TLSA & ORMP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Tiziana Life Sciences Ltd.

TLSA

Tiziana Life Sciences Ltd.

N/A

Current Price

$0.86

Market Cap

145.1M

Sector

Health Care

ML Signal

N/A

Logo Oramed Pharmaceuticals Inc.

ORMP

Oramed Pharmaceuticals Inc.

N/A

Current Price

$4.60

Market Cap

170.3M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
TLSA
ORMP
Founded
2013
2002
Country
United Kingdom
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
145.1M
170.3M
IPO Year
2017
2010

Fundamental Metrics

Financial Performance
Metric
TLSA
ORMP
Price
$0.86
$4.60
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
687.3K
211.6K
Earning Date
05-04-2026
05-14-2026
Dividend Yield
N/A
6.51%
EPS Growth
N/A
412.50
EPS
N/A
2.76
Revenue
N/A
$2,000,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
$1.67
Revenue Growth
N/A
49.25
52 Week Low
$0.87
$2.09
52 Week High
$2.35
$5.47

Technical Indicators

Market Signals
Indicator
TLSA
ORMP
Relative Strength Index (RSI) 32.91 45.69
Support Level N/A $3.91
Resistance Level $1.20 $5.10
Average True Range (ATR) 0.08 0.22
MACD -0.02 -0.07
Stochastic Oscillator 12.73 7.61

Price Performance

Historical Comparison
TLSA
ORMP

About TLSA Tiziana Life Sciences Ltd.

Tiziana Life Sciences Ltd is a clinical-stage biotechnology company that specializes in developing transformative therapies for neurodegenerative and neuroinflammatory diseases. The company's clinical pipeline includes drug assets for Non-Active Secondary Progressive Multiple Sclerosis, Multiple System Atrophy, Alzheimer's, and Amyotrophic Lateral Sclerosis. The company's mission is to design and deliver next-generation immunotherapies for neurodegenerative and neuroinflammatory diseases. The company's main immunotherapeutic candidate, Foralumab (TZLS-401), is being developed for Non-Active Secondary Progressive Multiple Sclerosis, Alzheimer's, and other CNS indications.

About ORMP Oramed Pharmaceuticals Inc.

Oramed Pharmaceuticals Inc is a pharmaceutical company that is engaged in the research and development of pharmaceutical solutions with a technology platform that allows for the oral delivery of therapeutic proteins. The company has developed an oral dosage form intended to withstand the harsh environment of the gastrointestinal tract and effectively deliver active insulin or other proteins. Its product pipeline includes ORMD-0801 for Diabetes, ORMD-0801 for NASH, and ORMD 0901.

Share on Social Networks: